A meta-analysis showed that XO inhibitors reduced the risk of end stage renal disease significantly and also improved estimated glomerular filtration rate (eGFR) from data from randomized controlled trials with long-term follow-up (>3 months) (38). This evidence concerns the gene XDH and chronic kidney disease.